48 completed, 14 recruiting, 14 unknown, 10 active not recruiting. 23 Not applicable, 20 Phase 3, 12 Phase 4, 11 Phase 2, 5 Phase 1.
Follow Atherosclerotic Cardiovascular Disease: new trials by email Literature Review of Atherosclerotic Cardiovascular Disease trials Research Report on Atherosclerotic Cardiovascular Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE Coronary Artery Calcium Scan, Carotid Artery Ultrasound, Lipoprotein(a) Measurement - Atherosclerotic Cardiovascular Disease | Recruiting | St. Jude Children's Research Hospital | 650 | 2026-09-21 | 2026-09-24 | |
| Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease Secukinumab (75 mg), Standard Medical Therapy - Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease | Phase 4 | Not yet recruiting | Peking University Third Hospital | 100 | 2026-07-15 | 2026-07-15 |
| AI-CCTA for Predicting Cardiovascular Events in CAD No intervention - Coronary Artery Disease, Atherosclerotic Cardiovascular Disease | Active not recruiting | Nanjing First Hospital, Nanjing Medical University | 3000 | 2026-06-01 | 2026-09-21 | |
| A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease HRS9531, HRS9531 placebo - Atherosclerotic Cardiovascular Disease | Phase 3 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 9262 | 2026-05-29 | 2026-09-08 |
| A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 5995 | 2026-04-02 | 2026-07-15 | |
| NOTIFY (New Observations Taking Information From Yesterday) CAC Notification, Clinician Guideline Reminder - Atherosclerotic Cardiovascular Disease | Not applicable | Withdrawn | Stanford University | 2026-03-01 | 2026-02-10 | |
| Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia Educational Material, Standard of care - Atherosclerotic Cardiovascular Disease | Phase 4 | Recruiting | Novartis Pharmaceuticals | 326 | 2025-11-26 | 2026-05-04 |
| Fish Oil, Metformin and Heart Health in PCOS Fish oil, Metformin, Fish Oil and Metformin - PCOS, Cardiovascular Disease | Phase 1 | Recruiting | University of Alberta | 146 | 2025-11-01 | 2025-12-12 |
| Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT) Initiation of tirzepatide, Initiation of sitagliptin - Type2 Diabetes Mellitus, Atherosclerotic Cardiovascular Disease | Completed | Brigham and Women's Hospital | 49065 | 2025-09-19 | 2026-04-30 | |
| Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management No treatment given - Atherosclerotic Cardiovascular Disease, Heart Failure | Completed | Novo Nordisk A/S | 608 | 2025-09-18 | 2026-02-11 | |
| Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure Regular Care, SBP PRS Dissemination - Hypertension, Atherosclerotic Cardiovascular Disease | Not applicable | Recruiting | University of Alabama at Birmingham | 300 | 2025-08-01 | 2026-10-09 |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Maridebart Cafraglutide, Placebo - Atherosclerotic Cardiovascular Disease, Overweight | Phase 3 | Recruiting | Amgen | 12800 | 2025-07-25 | 2026-10-08 |
| Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice Alirocumab 150 mg, Inclisiran - Atherosclerotic Cardiovascular Disease | Completed | Sanofi | 996 | 2025-05-22 | 2026-10-13 | |
| Pelacarsen Roll-over Extension Program Pelacarsen (TQJ230) - Atherosclerotic Cardiovascular Disease | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 599 | 2025-05-19 | 2026-10-14 |
| Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia Atorvastatin, Simvastatin, Rozuvastatin - Atherosclerotic Cardiovascular Disease | Recruiting | Novartis Pharmaceuticals | 2382 | 2025-04-15 | 2025-08-03 | |
| Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Followed by an Open-label Patient Cohort UDP-003, Placebo - Atherosclerotic Cardiovascular Disease, Acute Coronary Syndromes | Early Phase 1 | Recruiting | Cyclarity Therapeutics, Inc. | 84 | 2025-02-25 | 2026-09-25 |
| A Pragmatic INitiative for LDL-C Management by a CLinical Pharmacist-Led Team Among Atherosclerotic CardiovascUlar DisEase Patients Clinical Pharmacy Team, Usual Care - Atherosclerotic Cardiovascular Disease | Not applicable | Recruiting | Intermountain Health Care, Inc. | 400 | 2025-01-30 | 2025-05-06 |
| VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease Inclisiran - Atherosclerotic Cardiovascular Disease | Phase 4 | Active not recruiting | Duke University | 130 | 2024-12-16 | 2026-07-29 |
| A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacodynamics of AZD4144 in Participants With Established Atherosclerotic Cardiovascular and Chronic Kidney Disease. AZD4144, Placebo - Chronic Kidney Disease, Atherosclerotic Cardiovascular Disease | Phase 1 | Completed | AstraZeneca | 29 | 2024-12-09 | 2025-11-25 |
| A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure Placebo, AZD0780 - Atherosclerotic Cardiovascular Disease | Phase 2 | Completed | AstraZeneca | 202 | 2024-10-30 | 2026-02-18 |
Showing 20 of 95. Sign in to see all of them.
Atherosclerosis (95) · Cardiovascular Diseases (13) · Hypercholesterolemia (13) · Dyslipidemias (10) · Hyperlipoproteinemia Type II (9) · Myocardial Infarction (9) · Hyperlipidemias (8) · Coronary Artery Disease (7) · Diabetes Mellitus, Type 2 (4) · Peripheral Arterial Disease (4) · Vascular Diseases (4) · Heart Failure (3) · Hypertension (3) · Renal Insufficiency, Chronic (3) · Acute Coronary Syndrome (2)
Arterial Occlusive Diseases (94) · Arteriosclerosis (94) · Vascular Diseases (91) · Cardiovascular Diseases (82) · Nutritional and Metabolic Diseases (31) · Metabolic Diseases (30) · Lipid Metabolism Disorders (24) · Pathological Conditions, Signs and Symptoms (19) · Heart Diseases (17) · Pathologic Processes (15) · Dyslipidemias (14) · Myocardial Ischemia (13) · Hyperlipidemias (10) · Infarction (10) · Ischemia (10)
ALN-PCS (11) · evolocumab (7) · Atorvastatin (5) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (3) · Ezetimibe (3) · alirocumab (3) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (2) · Rosuvastatin Calcium (2) · Saline Solution (2) · anacetrapib (2) · Apolipoproteins A (1) · Arginine (1) · Aspirin (1) · Atenolol (1) · BMS-823778 (1)
Novartis Pharmaceuticals (11) · Amgen (3) · Duke University (3) · Esperion Therapeutics, Inc. (3) · Novo Nordisk A/S (3) · Sanofi (3) · University of Pennsylvania (3) · AstraZeneca (2) · China National Center for Cardiovascular Diseases (2) · Icahn School of Medicine at Mount Sinai (2) · NewAmsterdam Pharma (2) · Radboud University Medical Center (2) · Stanford University (2) · University of Florida (2) · University of Oxford (2)
United States (42) · China (16) · Netherlands (15) · United Kingdom (14) · Canada (13) · Germany (12) · South Korea (11) · France (9) · Japan (9) · Australia (8) · Denmark (8) · Italy (8) · Poland (8) · Spain (8) · Belgium (7)
Louise Bowman (2) · Ron Haberman, MD (2) · Adrian F. Hernandez, MD MHS FAHA (1) · Alexander Fanaroff, MD, MHS (1) · Alexander T Sandhu, MD, MS (1) · Ayman Hammoudeh, MD FACC (1) · Byeong-Keuk Kim (1) · Byeong-Keuk Kim, MD, PhD (1)
PMID 30403574, PMID 32609313, PMID 33990512, PMID 35916348, PMID 16110718, PMID 21543628, PMID 22180633, PMID 22696435, PMID 24161333, PMID 24239923, PMID 25440796, PMID 25773607, PMID 26039521, PMID 27602082, PMID 28304224, PMID 28306389, PMID 28847206, PMID 29653628, PMID 29735484, PMID 30423394, PMID 30487231, PMID 30760013, PMID 30898609, PMID 30922146, PMID 31117810, PMID 31248666, PMID 31272931, PMID 31331193, PMID 31466614, PMID 31475572, PMID 31504418, PMID 31553410, PMID 31630870, PMID 31707788, PMID 31707826, PMID 31800032, PMID 31887831, PMID 31948641, PMID 32131611, PMID 32186653, PMID 32223446, PMID 32370478, PMID 32381160, PMID 32466729, PMID 33051646, PMID 33078867, PMID 33438437, PMID 33722880, PMID 33755145, PMID 33995586
2016 (3), R01HL128056 (1), R01HL176882 (1), U01CA301480 (1)